GEMS: ART Resistance in Persons Diagnosed With HIV After PrEP Rollout in Sub-Saharan Africa

July 18-21, 2021; Virtual
While the number of PrEP breakthrough infections was small, there was a high frequency of ART resistance in HIV-infected persons on TDF-based PrEP in Kenya, Zimbabwe, Eswatini, and South Africa.
Format: Microsoft PowerPoint (.ppt)
File Size: 228 KB
Released: July 24, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Download CCO slides reviewing clinically relevant new data reported at IAS 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: September 13, 2021

Downloadable CCO slides from Daniel R. Kuritzkes, MD, on investigational HIV management approaches, including ARVs, bNAbs, vaccines, and cure

Babafemi Taiwo, MBBS
Program Director
Daniel R. Kuritzkes, MD
Released: September 9, 2021

Clinical Care Options (CCO): Dr Deniz Gökengin on Eastern European studies on HIV services and prevention during COVID-19, presented at IAS 2021

Deniz Gökengin, MD Released: September 1, 2021

Selecciones expertas de datos importantes sobre el VIH extraídos de IAS 2021, incluido el TAR actual y el experimental, la PrEP del VIH y el tratamiento de infecciones oportunistas.

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: August 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue